Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Stopped early · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving letrozole together with erlotinib may kill more tumor cells. PURPOSE: This phase II clinical trial is studying how well giving letrozole together with erlotinib works in treating postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive locally recurrent or metastatic breast cancer.

Key facts

Study ID

NCT00611715

Run by

Vanderbilt-Ingram Cancer Center

People needed

48

Starts

2003-11-01

Expected to finish

2008-12-01

Last updated by the study team

2012-08-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Central Georgia Hematology/Oncology Associates, P.C. — Macon, Georgia, United States
• Jennie Stuart Medical Center — Hopkinsville, Kentucky, United States
• Purchase Cancer Group — Paducah, Kentucky, United States
• Memorial Health Care System — Chattanooga, Tennessee, United States
• The Jones Clinic - Germantown — Germantown, Tennessee, United States
• Jackson-Madison County Hospital — Jackson, Tennessee, United States
• Tennessee Cancer Specialists — Knoxville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.